The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...

Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

Initial reports of increased suicidality in GLP-1 RA users compared with the general population raised concerns about the risk for this rare but serious adverse event, given the rising popularity ...

Their project, called Phytogene, harnesses the power of “biopharming” — a method that transforms plants into living drug ...

THURSDAY, March 6, 2025 (HealthDay News) -- GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study suggests. The drugs help manage patients ...

LINCOLN, Neb. (KOLN) - Popular GLP-1 drugs have been gaining traction across the United States as a means for weight loss. The drug has been approved to help treat type-2 diabetes, but a new study ...

Could a diabetes drug slash your cancer risk? New research shows GLP-1 receptor agonists may protect patients with type 2 diabetes from deadly blood cancers—beyond just managing blood sugar.

Noom, best-known for its weight loss app and more recent GLP-1 offering, launched an HRT program for menopause in late February, and telehealth company Hims & Hers plans to roll out at-home ...